Savant Capital, LLC Moderna, Inc. Transaction History

Savant Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	SELL	$101.21 - $166.61 $94,024 - $154,780	-929 Reduced 28.44%	2,338 $277,000
Q1 2024 May 03, 2024	BUY	$85.37 - $115.44 $19,037 - $25,743	223 Added 7.33%	3,267 $348,000
Q4 2023 Feb 05, 2024	SELL	$69.51 - $104.43 $20,157 - $30,284	-290 Reduced 8.7%	3,044 $302,000
Q3 2023 Nov 06, 2023	SELL	$96.41 - $126.61 $71,343 - $93,691	-740 Reduced 18.16%	3,334 $344,000
Q2 2023 Aug 04, 2023	BUY	$118.5 - $160.53 $201,805 - $273,382	1,703 Added 71.83%	4,074 $494,000
Q1 2023 May 02, 2023	BUY	$135.66 - $197.02 $35,000 - $50,831	258 Added 12.21%	2,371 $364,000
Q4 2022 Feb 06, 2023	BUY	$118.38 - $210.04 $46,168 - $81,915	390 Added 22.63%	2,113 $379,000
Q3 2022 Oct 28, 2022	BUY	$118.07 - $194.18 $203,434 - $334,572	1,723 New	1,723 $204,000
Q2 2022 Jul 22, 2022	SELL	$117.13 - $176.59 $152,971 - $230,626	-1,306 Closed	0 $0
Q1 2022 May 05, 2022	BUY	$126.46 - $235.05 $16,692 - $31,026	132 Added 11.24%	1,306 $225,000
Q4 2021 Feb 08, 2022	BUY	$225.82 - $368.51 $265,112 - $432,630	1,174 New	1,174 $298,000

954

241M

10.6M

18.7M

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $14.4B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

Get notified when there are updates to the investment portfolio of Savant Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Savant Capital, LLC with notifications on news.